AN2 Therapeutics, Inc.
ANTXHeld by 3 specialist biotech funds
High Convergence3 funds opened new positions. Short interest: 2.9% of float.
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.